#IDEAYA_Biosciences hashtag - Bluesky

@newsen.bsky.social

1 week ago

IDEAYA Biosciences Enrolls First Patient in Phase 1 Clinical Trial for Innovative Cancer Treatment IDE574 IDEAYA Biosciences has commenced its Phase 1 trial for IDE574, a promising dual inhibitor targeting KAT6 and KAT7 in various solid tumors, showing hope for patients with challenging cancers.

IDEAYA Biosciences Enrolls First Patient in Phase 1 Clinical Trial for Innovative Cancer Treatment IDE574 #United_States #IDEAYA_Biosciences #South_San_Francisco #KAT6/7 #IDE574

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

IDEAYA Biosciences Initiates First Patient Enrollment in Innovative Phase 1 Combination Clinical Study IDEAYA Biosciences announces the commencement of their Phase 1 clinical trial combining IDE849 and IDE161 for treating various solid tumors, including SCLC and melanoma.

IDEAYA Biosciences Initiates First Patient Enrollment in Innovative Phase 1 Combination Clinical Study #United_States #IDEAYA_Biosciences #South_San_Francisco #IDE161 #IDE849

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

IDEAYA Biosciences Makes Strategic Inducement Grants to New Employees On March 26, 2026, IDEAYA Biosciences announced stock option grants to new hires as part of its commitment to attract talent and drive oncology drug development.

IDEAYA Biosciences Makes Strategic Inducement Grants to New Employees #United_States #NASDAQ #stock_options #IDEAYA_Biosciences #South_San_Francisco

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Upcoming Investor Events and New Updates on IDEAYA's Darovasertib Trial Results IDEAYA Biosciences announces its participation in key investor relations events and provides the latest guidance on Darovasertib trial results.

Upcoming Investor Events and New Updates on IDEAYA's Darovasertib Trial Results #United_States #oncology #IDEAYA_Biosciences #South_San_Francisco #darovasertib

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 weeks ago

IDEAYA Biosciences to Showcase Cutting-Edge Cancer Research at AACR 2026 Annual Meeting IDEAYA Biosciences reveals three important presentations at AACR 2026, showcasing novel therapies targeting various cancers through innovative scientific approaches.

IDEAYA Biosciences to Showcase Cutting-Edge Cancer Research at AACR 2026 Annual Meeting #United_States #San_Diego #biopharmaceuticals #Cancer_Research #IDEAYA_Biosciences

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

IDEAYA Biosciences Enrolls First Patient for Phase 1 Clinical Trial of IDE892, Targeting MTAP-Deleted Solid Tumors IDEAYA Biosciences has begun its Phase 1 trial for IDE892, a promising PRMT5 inhibitor aimed at treating MTAP-deleted solid tumors, including NSCLC and pancreatic cancer.

IDEAYA Biosciences Enrolls First Patient for Phase 1 Clinical Trial of IDE892, Targeting MTAP-Deleted Solid Tumors #United_States #IDEAYA_Biosciences #South_San_Francisco #PRMT5_Inhibitor #IDE892

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

IDEAYA Biosciences Grants Stock Options Incentives Under New Employment Plan IDEAYA Biosciences has announced the grant of stock options to three new hires under its Employment Inducement Incentive Award Plan, aligning with Nasdaq Listing requirements.

IDEAYA Biosciences Grants Stock Options Incentives Under New Employment Plan #NASDAQ #US #stock_options #IDEAYA_Biosciences #South_San_Francisco

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

First Patient Enrolled for IDEAYA's Innovative Cancer Treatment Trial with IDE034 IDEAYA Biosciences has announced the enrollment of its first patient in the Phase 1 trial of IDE034, targeting specific types of cancers with promising results.

First Patient Enrolled for IDEAYA's Innovative Cancer Treatment Trial with IDE034 #United_States #IDEAYA_Biosciences #South_San_Francisco #Cancer_Trials #IDE034

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

IDEAYA Biosciences Welcomes Dr. Theodora Ross as Chief Development Officer IDEAYA Biosciences has appointed Dr. Theodora Ross as Chief Development Officer, enhancing its oncology pipeline and strategic direction.

IDEAYA Biosciences Welcomes Dr. Theodora Ross as Chief Development Officer #United_States #IDEAYA_Biosciences #South_San_Francisco #Dr._Theodora_Ross #oncology_pipeline

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

IDEAYA Biosciences Set to Showcase Innovations in Upcoming Investor Events February 2026 IDEAYA Biosciences will participate in key investor relations events in February 2026, highlighting its advancements in oncology and precision medicine.

IDEAYA Biosciences Set to Showcase Innovations in Upcoming Investor Events February 2026 #oncology #IDEAYA_Biosciences #Precision_Medicine

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

IDEAYA Biosciences Unveils New Employee Stock Options Incentive Plan IDEAYA Biosciences announces the grant of non-qualified stock options to a new hire, boosting its talent pool under Nasdaq Listing Rule 5635(c)(4).

IDEAYA Biosciences Unveils New Employee Stock Options Incentive Plan #United_States #NASDAQ #stock_options #IDEAYA_Biosciences #South_San_Francisco

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

IDEAYA Biosciences Announces 2026 Objectives at J.P. Morgan Healthcare Conference IDEAYA Biosciences shared insights into its 2026 corporate objectives at the J.P. Morgan Healthcare Conference, reflecting its commitment to oncology advancements.

IDEAYA Biosciences Announces 2026 Objectives at J.P. Morgan Healthcare Conference #United_States #IDEAYA_Biosciences #South_San_Francisco #uveal_melanoma #darovasertib

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

IDEAYA Biosciences Set to Present at J.P. Morgan Healthcare Conference 2026 IDEAYA Biosciences, a leading oncology firm, will present at the 44th Annual J.P. Morgan Healthcare Conference, aiming to discuss advancements in precision medicine.

IDEAYA Biosciences Set to Present at J.P. Morgan Healthcare Conference 2026 #United_States #San_Francisco #oncology #J.P._Morgan #IDEAYA_Biosciences

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

IDEAYA Biosciences Reports Key Milestone in Phase 2/3 Clinical Trial for Uveal Melanoma Treatment IDEAYA Biosciences has successfully completed its target enrollment for a Phase 2/3 trial of darovasertib in uveal melanoma. Results expected in early 2026.

IDEAYA Biosciences Reports Key Milestone in Phase 2/3 Clinical Trial for Uveal Melanoma Treatment #United_States #IDEAYA_Biosciences #South_San_Francisco #uveal_melanoma #darovasertib

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

IDEAYA Biosciences Advances Cancer Treatment with IND Submission for IDE574 Dual Inhibitor IDEAYA Biosciences has submitted an IND application for IDE574, a potential first-in-class dual inhibitor targeting breast and lung cancers, starting trials in early 2026.

IDEAYA Biosciences Advances Cancer Treatment with IND Submission for IDE574 Dual Inhibitor #USA #Cancer_Treatment #IDEAYA_Biosciences #South_San_Francisco #IDE574

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

IDEAYA Biosciences Announces Employee Stock Options Under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences has granted stock options to a new employee, demonstrating its commitment to growth and innovation in targeted oncology therapies.

IDEAYA Biosciences Announces Employee Stock Options Under Nasdaq Listing Rule 5635(c)(4) #United_States #NASDAQ #stock_options #IDEAYA_Biosciences #South_San_Francisco

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

IDEAYA Biosciences to Engage Investors at Major Conferences in December 2025 IDEAYA Biosciences, a leader in precision oncology, confirms participation in prominent investor relations events set for December 2025.

IDEAYA Biosciences to Engage Investors at Major Conferences in December 2025 #USA #oncology #IDEAYA_Biosciences #South_San_Francisco #Precision_Medicine

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

IDEAYA Biosciences Reports Strong Third Quarter 2025 Financial Results and Pipeline Developments IDEAYA Biosciences announces its third quarter 2025 financial results, marking significant progress in clinical trials and strategic partnerships to enhance its oncology portfolio.

IDEAYA Biosciences Reports Strong Third Quarter 2025 Financial Results and Pipeline Developments #United_States #oncology #IDEAYA_Biosciences #South_San_Francisco #darovasertib

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

IDEAYA Biosciences Grants Stock Options to New Employees in Accordance with Nasdaq Rules IDEAYA Biosciences has granted stock options to new hires under Nasdaq's regulations, reinforcing its commitment to targeted cancer therapies.

IDEAYA Biosciences Grants Stock Options to New Employees in Accordance with Nasdaq Rules #United_States #NASDAQ #stock_options #IDEAYA_Biosciences #South_San_Francisco

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

IDEAYA Biosciences Unveils Encouraging Results for Darovasertib in Uveal Melanoma Treatment at ESMO 2025 IDEAYA Biosciences has announced positive Phase 2 data for Darovasertib in the treatment of primary uveal melanoma, showing promising tumor reduction and eye preservation rates.

IDEAYA Biosciences Unveils Encouraging Results for Darovasertib in Uveal Melanoma Treatment at ESMO 2025 #United_States #IDEAYA_Biosciences #South_San_Francisco #uveal_melanoma #darovasertib

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

IDEAYA Biosciences Achieves Groundbreaking Survival Data in Uveal Melanoma Trials IDEAYA Biosciences presents promising clinical trial data revealing a median overall survival of 21.1 months for uveal melanoma patients, marking significant progress in treatment.

IDEAYA Biosciences Achieves Groundbreaking Survival Data in Uveal Melanoma Trials #United_States #IDEAYA_Biosciences #South_San_Francisco #uveal_melanoma #darovasertib

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

IDEAYA Biosciences Unveils New Inducement Grants Under Nasdaq Regulations IDEAYA Biosciences has announced the granting of stock options to new employees as part of their employment strategy per Nasdaq regulations.

IDEAYA Biosciences Unveils New Inducement Grants Under Nasdaq Regulations #United_States #NASDAQ #stock_options #IDEAYA_Biosciences #South_San_Francisco

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

IDEAYA Biosciences Presents Positive Phase 1/2 Trial Results for IDE397 and Trodelvy in Rare Urothelial Cancer IDEAYA Biosciences reports promising results from a Phase 1/2 trial involving IDE397 and Trodelvy for patients with MTAP-deletion urothelial cancer. The study shows positive response rates, paving the way for further investigations.

IDEAYA Biosciences Presents Positive Phase 1/2 Trial Results for IDE397 and Trodelvy in Rare Urothelial Cancer #United_States #IDEAYA_Biosciences #South_San_Francisco #Trodelvy #IDE397

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago